Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aethlon Medical, Inc. (NASDAQ: AEMD).

Full DD Report for AEMD

You must become a subscriber to view this report.


Recent News from (NASDAQ: AEMD)

Research Report Identifies Ball, Aethlon Medical, NeoGenomics, Del Taco Restaurants, Arconic, and Agilysys with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ball Corporation (NYSE:BLL), Aethlon Medical, Inc. (NASDAQ:AEMD), NeoGeno...
Source: GlobeNewswire
Date: August, 27 2018 08:00
Aethlon Medical, Inc. (AEMD) CEO Jim Joyce on Q1 2019 Results - Earnings Call Transcript
Aethlon Medical, Inc. (AEMD) Q1 2019 Earnings Conference Call August 8, 2018 16:30 ET Executives Jim Frakes - CFO Jim Joyce - CEO Analysts Brian Marckx - Zacks Investment Research Yi Chen - H.C. Wainwright Marc Robins - Catalyst Research Presentation Operator Go...
Source: SeekingAlpha
Date: August, 09 2018 02:20
Aethlon Medical Announces First Quarter Fiscal Year 2019 Results
SAN DIEGO , Aug. 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal first quarter ended June 30, 2018 . First Quarter Financial Results At...
Source: PR Newswire
Date: August, 08 2018 16:15
Aethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2019 and Host Conference Call on August 8, 2018
SAN DIEGO , Aug. 2, 2018  /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the first quarter fiscal year 2019 ended June 30, 2018 at 4:1...
Source: PR Newswire
Date: August, 02 2018 08:15
Aethlon Medical issues Hemopurifier patent to treat life-threatening viruses, shares up 3% premarket
Aethlon Medical (NASDAQ: AEMD ) announces the issuance of U.S. Patent No. 10,022,483. More news on: Aethlon Medical, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: July, 23 2018 09:13
Aethlon Medical Announces Issuance of Hemopurifier® Patent To Treat Life-Threatening Viruses
SAN DIEGO , July 23, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the issuance of U.S. Patent No. 10,022,483 ("the '483 Patent").  The '483 Patent protects...
Source: PR Newswire
Date: July, 23 2018 08:15
Guy Cipriani Joins Aethlon Medical's Board of Directors
SAN DIEGO , June 25, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Guy Cipriani to its Board of Directors. Mr. Cipriani qualifies as an independe...
Source: PR Newswire
Date: June, 25 2018 09:15
New Research: Key Drivers of Growth for Nicolet Bankshares, Vitamin Shoppe, Aethlon Medical, Barrett Business Services, Veracyte, and TPG Specialty Lending - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, June 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Nicolet Bankshares Inc. (NASDAQ:NCBS), Vitamin Shoppe, Inc (NYSE:VSI), Ae...
Source: GlobeNewswire
Date: June, 21 2018 07:55
Aethlon Medical, Inc. (AEMD) CEO Jim Joyce on Q4 2018 Results - Earnings Call Transcript
Aethlon Medical, Inc. (AEMD) Q4 2018 Earnings Conference Call June 08, 2018 04:30 PM ET Executives Jim Frakes - Chief Financial Officer Jim Joyce - Chief Executive Officer Analysts Brian Marckx - Zacks Investment Research Yi Chen - H.C. Wainwright Presentation Operat...
Source: SeekingAlpha
Date: June, 08 2018 18:17
Aethlon Medical beats by $0.02
Aethlon Medical (NASDAQ: AEMD ): FY EPS of -$0.46 beats by $0.02 . More news on: Aethlon Medical, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: June, 08 2018 16:18

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-121.271.301.331.23992,487
2018-12-111.261.25241.291.23137,923
2018-12-101.251.251.251.2176,612
2018-12-071.291.271.29471.22218,305
2018-12-061.271.30011.311.26113,840

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1211,63935,26433.0053Cover
2018-12-1121,10971,40829.5611Cover
2018-12-1018,31931,02659.0440Short
2018-12-0744,39281,37754.5510Short
2018-12-0634,39752,89865.0251Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AEMD.


About Aethlon Medical, Inc. (NASDAQ: AEMD)

Logo for Aethlon Medical, Inc. (NASDAQ: AEMD)

The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life threatening conditions. The Aethlon ADAPT system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier, a device with broad spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non government research organizations, the Hemopurifier is also a leading broad spectrum treatment candidate to address bioterror and pandemic threats.

 

Contact Information

 

 

Current Management

  • James Allen Joyce / CEO
  • Rodney S. Kenley / President
  • James Brenton Frakes / CFO
  • Richard Tullis / CSO
  • John Salvador / Director, Inv. Rel., Director, Corp. Comm.
  • Charlene Owen / Assistant to the CFO
  • James Allen Joyce / Chairman
  • Edward G. Broenniman /
  • Franklyn S. Barry, Jr. /
  • Rodney S. Kenley /
  • Cheetah S. Shah, MD /

Current Share Structure

  • Market Cap: $26,528,522 - 03/20/2018
  • Issue and Outstanding: 16,580,326 - 01/31/2018
  • Float: 4,790,301 - 05/12/2015

 


Recent Filings from (NASDAQ: AEMD)

Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 24 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 24 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 06 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 06 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: February, 20 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: February, 20 2018

 

 


Daily Technical Chart for (NASDAQ: AEMD)

Daily Technical Chart for (NASDAQ: AEMD)


Stay tuned for daily updates and more on (NASDAQ: AEMD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AEMD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AEMD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AEMD and does not buy, sell, or trade any shares of AEMD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/